Viridian Therapeutics, Inc.(VRDN)Earnings, Financials & Key RatiosViridian Therapeutics, Inc. (VRDN) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on a single therapeutic mechanism and a $119.7 million quarterly cash burn rate present significant binary risks that outweigh current liquidity buffers.
Viridian Therapeutics, Inc. (VRDN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Viridian Therapeutics, Inc. (VRDN) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.90vs $1.06+15.1% | $141,000vs $36,083+290.8% |
| Q1 2026 | Feb 26, 2026 | $1.08vs $0.90-20.0% | $132,000vs $18M-99.3% |
| Q4 2025 | Nov 5, 2025 | $0.34vs $0.82+58.5% | $71Mvs $16M+348.1% |
| Q3 2025 | Aug 6, 2025 | $1.00vs $1.00+0.0% | $75,000 |
Recent stock market news and headlines for Viridian Therapeutics, Inc. (VRDN)
Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.
Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen's Tepezza in thyroid eye disease. Lumvoa's shorter infusion course, inclusion of chronic TED data, and immediate availability position VRDN for commercial success, though management is tempering near-term revenue expectations. Elegrobart's underwhelming REVEAL-1 phase 3 results limit its competitive edge in active TED but highlight its convenience and potential in underpenetrated chronic TED based on REVEAL-2 study results.
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript
The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN) new thyroid eye disease (TED) treatment, Lumvoa (veligrotug-vvze).
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED). TED is a rare, debilitating autoimmune disease characterized by inflammation and tissue remodeling around and behind the.
Key metrics vs top competitors for Viridian Therapeutics, Inc. (VRDN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $20.47 | $1.74B | -6.17 | 23359.93% | -483.56% | -49.16% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $67.24 | $948.68M | 73.89 | 20.03% | 14.99% | 13.98% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $368.10 | $198.66B | 25.87 | 9.92% | 20.95% | 89.41% | — |
Viridian Therapeutics, Inc. (VRDN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Viridian Therapeutics, Inc. (VRDN) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
May 5, 2026·SEC
Mar 30, 2026·SEC
Get notified when VRDN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Viridian Therapeutics, Inc. (VRDN) stock FAQ — growth, dividends, profitability & financials explained
Viridian Therapeutics, Inc. (VRDN) reported $70.9M in revenue for fiscal year 2025. This represents a 1510% increase from $4.4M in 2012.
Viridian Therapeutics, Inc. (VRDN) grew revenue by 23359.9% over the past year. This is strong growth.
Viridian Therapeutics, Inc. (VRDN) reported a net loss of $360.6M for fiscal year 2025.
Viridian Therapeutics, Inc. (VRDN) has a return on equity (ROE) of -49.2%. Negative ROE indicates the company is unprofitable.
Viridian Therapeutics, Inc. (VRDN) had negative free cash flow of $303.8M in fiscal year 2025, likely due to heavy capital investments.
